In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Aerovance spins out of Bayer, raises $32mm

Executive Summary

Bayer AG has spun off a new US biopharmaceutical company called Aerovance (therapeutics for inflammatory, autoimmune, and respiratory diseases), which raised $32mm with its first institutional venture financing. Apax Partners led the round and was joined by Lehman Brothers, NGN Capital, and Burrill & Co.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies